vaccine – pharma.markets

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Authorization for Children 6 Months through 4 Years of Age

17/06/2022 MaP 0

In a Phase 2/3 clinical trial, the Pfizer-BioNTech COVID-19 Vaccine elicited a strong immune response in this age group Three 3-µg doses had favorable safety […]

BioNTech introduces first modular mRNA manufacturing facility to promote scalable vaccine production in Africa

16/02/2022 MaP 0

Developing turnkey solution to enable mRNA-based vaccine production in modular and scalable sites installed by BioNTech Presidents of Ghana, Rwanda, Senegal, the Director-General of the […]

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request from U.S. FDA

01/02/2022 MaP 0

With pediatric COVID-19 cases surpassing 10 million and at the request of the FDA, the companies have submitted available data on the safety and efficacy […]

Pfizer and BioNTech Publish Data from Two Laboratory Studies on COVID-19 Vaccine-induced Antibodies Ability to Neutralize SARS-CoV-2 Omicron Variant

24/01/2022 MaP 0

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the publication of new results from two laboratory studies demonstrating that three doses of […]

Spanish vaccine shows good results against omicron variant

05/01/2022 MaP 0

The future Spanish vaccine against covid, on which the Hipra laboratories based in Amer (Girona) are working, is showing good results against the omicron variant, […]

Novavax Announces Initial Omicron Cross-Reactivity Data from COVID-19 Vaccine Booster and Adolescent Studies

23/12/2021 MaP 0

– Two-dose primary regimen of NVX-CoV2373 demonstrated cross-reactive immune responses against Omicron (B.1.1.529) and other variants – Third dose produced increased immune responses comparable to […]

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older

10/12/2021 MaP 0

PDF Version First emergency use authorization in the United States for a COVID-19 vaccine booster in individuals 16 years and older Pfizer Inc. (NYSE: PFE) […]

News on Spanish vaccine PHH-1V from HIPRA and the new B.1.1.159 variant

27/11/2021 MaP 0

Spanish company Hipra says it could adapt its vaccine PHH-1V to a new variant B.1.1.529 within four months The Spanish company expects to receive approval […]

AEMPS authorizes Phase IIb clinical trial of HIPRA Covid-19 vaccine

16/11/2021 MaP 0

The main objectives are to confirm safety and tolerability for a booster dose and to check if the booster dose prolongs the immune response to […]

The Spanish vaccine against covid, close to commercialisation

30/10/2021 MaP 0

The Government approves funding to Hipra laboratories for its serum to advance to the final stages of clinical trials before its commercialisation. EFE The Centre […]

Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years

30/10/2021 MaP 0

Emergency Use Authorization (EUA) is supported by clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 through 11 […]

Pfizer and BioNTech Announce Submission of Initial Data to U.S. FDA to Support Booster Dose of COVID-19 Vaccine

16/08/2021 MaP 0

Phase 1 safety and immunogenicity data in individuals who received a third dose of the Pfizer-BioNTech vaccine (BNT162b2) show a favorable safety profile and robust […]